To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for previously treated advanced hepatocellular carcinoma.
Status In progress
Process STA 2018
ID number 3917

Provisional Schedule

Expected publication 23 March 2022

Project Team

Project lead Louise Jafferally

Email enquiries


Key events during the development of the guidance:

Date Update
19 March 2021 - 13 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 February 2021 In progress. Topic in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance